Epiminder Wins FDA Clearance to Extend Minder Use to Adolescents
EPI: $0.265 +0.00% · MC: $61M
The FDA cleared Epiminder’s Minder system for patients aged 12 and older, expanding eligibility from adults aged 18 and above to include adolescents with drug-resistant epilepsy. Separately, DETECT enrolment reached 100 patients ahead of the company’s November target and is now past halfway towards its planned enrolment of up to 210; Epiminder says it remains on track to complete enrolment by the end of the first half of 2027. The company reported cash of approximately $65 million at September’s end, with no borrowings, and said this is expected to fund activities well into 2028.

Comments